Compare PETZ & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PETZ | CTXR |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 13.4M |
| IPO Year | 2017 | 2010 |
| Metric | PETZ | CTXR |
|---|---|---|
| Price | $1.14 | $0.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.6K | ★ 296.8K |
| Earning Date | 11-27-2026 | 12-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $104.18 |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.37 |
| 52 Week High | $1.83 | $1.54 |
| Indicator | PETZ | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 51.49 |
| Support Level | $1.11 | $0.52 |
| Resistance Level | $1.37 | $0.63 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 63.83 | 33.33 |
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.